Biogen Product Adulelm Approved for Alzheimer's Disease
The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc's (BIIB) Alzheimer disease product Adulelm (aducanumab). Although the approval seemed to be great news for Biogen many analysts and researchers, in highly regarded scientific institutions and universities, called it controversial. The FDA advisory committee has voted almost . . .
This content is for paid subscribers.
Trick or Trade June 12, 2021